Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|May 15, 2025
Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting
Author(s)Ashley Chan
Fact checked by: Caroline Seymour
Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.
Advertisement
Advertisement
With the
Related to this article
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
The combination met its primary end point in the phase 3 SANOVO trial, though full efficacy and safety data have not yet been reported.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
Advertisement
Advertisement